

E Y V A

S u m m a r y

Eyva X: Upgraded charging dock, premium packaging, portability and in-built battery planned.

Pre-Launch: 3 phases done, 2 to go; strong 40–55 aged audience traction in metabolic & daily vitals tracking.

OND Metrics: \$300K orderbook, 66% revenue conversion, 18% retention, 8–12 min engagement, 1:6 CAC.

Clinical Validation: Independently evaluated; accepted in a PubMed-indexed journal, strengthening scientific credibility.

Eyva X Progress

We've also upgraded to premium, **higher-quality packaging boxes**, creating a more refined and memorable unboxing experience.



EyvaX Progress



We've developed a **redesigned charging dock** with improved build quality and a more seamless everyday user experience.

Portability is also being factored into the design, with future plans to introduce an in-built battery option to make charging more flexible and convenient for users on the go.



EyvaX Progress

EyvaX progress is moving forward with **new app screens** being introduced, which will go live for beta users by mid-March for testing and feedback.



T e a m G r o w t h

Team growth is progressing steadily, with new members joining the **Administration, Marketing,** and **Software** departments, strengthening collaboration and improving overall operational efficiency.



Market Expansions

We've **completed three pre-launch phases with two more planned** before the official launch, helping us steadily build lead generation and buyer pipeline.

Our core audience is shaping up around the **35–55 age group**, aligning well with our intended user profile for EYVA

We're receiving a strong response, **especially around metabolic insights** and day-to-day biomarker tracking, indicating clear user interest and relevance.



Revenue & Performance Highlights

Orderbook for OND Quarter **300,000\$** with prebooking advance.

Revenue - **66%**

Customer Retention - 18% LTV from 2022

Avg. Customer Active Time - 8 - 12 Mins

CAC - 1:6

O u r R e s e a r c h

Independent Clinical Validation Update

As part of our commitment to building scientifically robust wellness metrics, EYVA underwent an **independent comparative evaluation** conducted by clinicians from **AIG Hospitals and Apollo-affiliated doctors**.

O u r R e s e a r c h

Study Focus

Comparative assessment of EYVA against established home use devices under real-world conditions.

Outcome

The research manuscript has been accepted for publication in the **International Journal of Research in Medical Sciences (IJRMS)** – a PubMed-indexed medical journal.

Why This Matters

- Independent external validation
- Peer-reviewed scientific credibility
- Strengthens long-term global positioning and brand value for EYVA

Investment Updates

We've recently secured a **\$1 Mn** investment this quarter



This marks a remarkable turnaround far exceeding our initial ask.

This reflects strong investor confidence and a clear path to scaling.

Thank You

for Your Continued Support

We appreciate your trust and support as we continue to grow and innovate. If you have any questions or would like further details on any of the updates, feel free to reach out.

Thank you for being part of the EYVA journey, and I look forward to updating you again soon!